Non Small Cell Lung Cancer - EGFR inhibitor - DDR + EGFR mutation

Association details:

Biomarker:	DDR + EGFR mutation
Cancer:	Non Small Cell Lung Cancer
Drug Class:	EGFR inhibitor
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

ESMO 2021

Title:

1229P-Co-mutation of DNA damage repair (DDR) genes influence the efficiency of EGFR-TKIs in NSCLC patients harboring EGFR activating mutations

Published date:

09/13/2021

Excerpt:

The efficiency results showed the median progression free survival (mPFS) of patients with EGFR+/DDR+ and EGFR+/DDR-receiving EGFR-TKIs were 6.3 months (cohort 1) and 12.0 months (cohort 2) respectively…Co-mutation of DDR genes influence the efficiency of EGFR-TKIs in NSCLC patients harboring EGFR activating mutations.